Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines across respiratory, infectious, and gastrointestinal diseases. It emphasizes the creation of targeted therapies with novel mechanisms of action, leveraging its proprietary drug delivery platforms and respiratory expertise to address unmet medical needs.
Company News
Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday. Shares of Logitech International S.A. (NASDAQ: LOGI) fell sharply in today’s pre-market trading after the company reported third-quarter results. Logitech International posted quarterly earnings of $1.53 per share, versus market estima...